Macquarie 08/03/2010 3 Neutral $37.48 5.0%
The broker notes the FDA in the US has approved the company's licence application for Hizentra and it sees this as a clear positive for the group even though Hizentra sales will eventually cannibalise Vivaglobin sales.
With no changes to its earnings forecasts on the news the broker retains its Neutral rating.
credit suisse - $40.50, page-12
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.00 |
Change
2.260(0.78%) |
Mkt cap ! $141.5B | |||
| Open | High | Low | Value | Volume |
| $294.00 | $294.75 | $290.82 | $491.6M | 1.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8192 | $292.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.06 | 12368 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |